Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 37.59 kDa 
• Atom Count: 2487 
• Residue Count: 301 
• Unique protein chains: 1

4NUS

Rsk2 N-terminal kinase in complex with LJH685

• DOI: 10.2210/pdb4NUS/pdb

• Classification: TRANSFERASE/TRANSFERASE INHIBITOR
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): No 


• Deposited: 2013-12-04 Released: 2014-03-05 
• Deposition Author(s): Appleton, B.A.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.39 Å
• R-Value Free: 0.231 
• R-Value Work: 0.189 
• R-Value Observed: 0.191 

Literature

Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers.

Aronchik, I., Appleton, B.A., Basham, S.E., Crawford, K., Del Rosario, M., Doyle, L.V., Estacio, W.F., Lan, J., Lindvall, M.K., Luu, C.A., Ornelas, E., Venetsanakos, E., Shafer, C.M., Jefferson, A.B.

(2014) Mol Cancer Res 12: 803-812

• PubMed: 24554780 
• DOI: 10.1158/1541-7786.MCR-13-0595
• Structures With Same Primary Citation


• PubMed Abstract: 
  

The p90 ribosomal S6 kinase (RSK) family of serine/threonine kinases is expressed in a variety of cancers and its substrate phosphorylation has been implicated in direct regulation of cell survival, proliferation, and cell polarity. This study characterizes and presents the most selective and potent RSK inhibitors known to date, LJH685 and LJI308. Structural analysis confirms binding of LJH685 to the RSK2 N-terminal kinase ATP-binding site and reveals that the inhibitor adopts an unusual nonplanar conformation that explains its excellent selectivity for RSK family kinases. LJH685 and LJI308 efficiently inhibit RSK activity in vitro and in cells. Furthermore, cellular inhibition of RSK and its phosphorylation of YB1 on Ser102 correlate closely with inhibition of cell growth, but only in an anchorage-independent growth setting, and in a subset of examined cell lines. Thus, RSK inhibition reveals dynamic functional responses among the inhibitor-sensitive cell lines, underscoring the heterogeneous nature of RSK dependence in cancer.

---

Organizational Affiliation: 

Authors' Affiliations: Novartis Institutes for BioMedical Research, Emeryville, California; and 2Shanghai Haiyan Pharmaceutical Technology Co., Ltd., Shanghai.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Ribosomal protein S6 kinase alpha-3	A	323	Homo sapiens	Mutation(s): 0  Gene Names: RPS6KA3, ISPK1, MAPKAPK1B, RSK2 EC: 2.7.11.1
Find proteins for P51812 (Homo sapiens) Explore P51812  Go to UniProtKB:  P51812
NIH Common Fund Data Resources
PHAROS  P51812 GTEx  ENSG00000177189

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
2NK	A	2,6-difluoro-4-{4-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl}phenol C22 H21 F2 N3 O IKUFKDGKRLMXEX-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
2NK	IC50:  5   nM  Binding MOAD
2NK	IC50:  5   nM  BindingDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.39 Å
• R-Value Free: 0.231 
• R-Value Work: 0.189 
• R-Value Observed: 0.191 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 52.271	α = 90
b = 62.812	β = 90
c = 117.244	γ = 90

Software Package:

Software Name	Purpose
BUSTER	refinement
PROCESS	data reduction
PROCESS	data scaling

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2013-12-04 
• Released Date: 2014-03-05 
Deposition Author(s): Appleton, B.A.

Revision History 

• Version 1.0: 2014-03-05
  Type: Initial release
  
• Version 1.1: 2014-11-12
  Changes: Database references